| abstract |
The compounds of formula (I), where the groups have the meanings defined in the description of the invention, are useful in the manufacture of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of Na, K-ATPase. They are useful in the manufacture of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as progression of renal failure in autosomal dominant polycystic kidney disease (ADPKD), pre-eclampic hypertension and proteinuria, and progression of renal failure in patients with aducin polymorphism. |